XORTX Therapeutics Files 2024 Annual Report
Ticker: XRTX · Form: 20-F · Filed: May 12, 2025 · CIK: 1729214
Sentiment: neutral
Topics: annual-report, pharmaceuticals, financing
TL;DR
XORTX dropped its 2024 20-F, check out the latest on their pharma biz and financing rounds.
AI Summary
XORTX Therapeutics Inc. filed its annual report on Form 20-F for the fiscal year ending December 31, 2024. The company, incorporated in A1 and headquartered in Vancouver, operates in the Pharmaceutical Preparations sector. Key dates mentioned include various offerings and warrant issuances throughout 2022, 2023, and 2024, with specific transactions on October 7, 2022, February 15, 2024, March 4, 2024, and October 18, 2024.
Why It Matters
This filing provides investors with a comprehensive overview of XORTX Therapeutics' financial performance, business operations, and risk factors for the fiscal year 2024, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, XORTX faces inherent risks related to drug development, regulatory approvals, and market competition, which are detailed in the 20-F filing.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Filer of the 20-F report
- 2024-12-31 (date) — Fiscal year end
- 2025-05-12 (date) — Filing date of the 20-F
- Vancouver (location) — Company headquarters city
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
- 2022-10-07 (date) — Date of a Finders Warrants and Ifrs Private Placement transaction
- 2024-03-04 (date) — Date of a Major Ordinary Share Transactions and NonBrokeredOffering
- 2024-02-15 (date) — Date of a Major Ordinary Share Transactions and NonBrokeredOffering
- 2024-10-18 (date) — Date of a PreFundedUnits, PreFundedWarrants, and RegisteredDirectOfferingAndPrivatePlacement transaction
FAQ
What is the primary business of XORTX Therapeutics Inc. as described in the 20-F?
XORTX Therapeutics Inc. operates in the Pharmaceutical Preparations sector, as indicated by its SIC code 2834.
When did XORTX Therapeutics Inc. file its 20-F for the fiscal year ending December 31, 2024?
The 20-F filing was made on May 12, 2025.
What specific types of financial transactions are mentioned in the filing for 2024?
The filing mentions a RegisteredDirectOfferingAndPrivatePlacement on October 18, 2024, involving PreFundedUnits and PreFundedWarrants.
Are there any specific dates mentioned for non-brokered offerings or share transactions?
Yes, the filing notes Major Ordinary Share Transactions and NonBrokeredOffering events on March 4, 2024, and February 15, 2024.
Where is XORTX Therapeutics Inc. headquartered?
XORTX Therapeutics Inc. is headquartered in Vancouver.
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on May 12, 2025 regarding XORTX Therapeutics Inc. (XRTX).